array:19 [
  "pii" => "X0211699500025862"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:14-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1599
    "formatos" => array:3 [
      "EPUB" => 174
      "HTML" => 1156
      "PDF" => 269
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025854"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:16-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2256
      "formatos" => array:3 [
        "EPUB" => 162
        "HTML" => 1700
        "PDF" => 394
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Papel del TGF- ?1 en la progresión de la Nefropatía Crónica del Injerto renal. Efecto del Bloqueo de la Angiotensina II"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "16"
          "paginaFinal" => "17"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. M. CAMPISTOL"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. M. CAMPISTOL"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025854?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025854/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025870"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2160
      "formatos" => array:3 [
        "EPUB" => 148
        "HTML" => 1629
        "PDF" => 383
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Efectos del Losartan en los cambios de las uniones intercelulares endoteliales mediados por Angiotensina II"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "13"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. ÁLVAREZ CHIVA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. ÁLVAREZ CHIVA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025870?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025870/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Angiotensin II and TGF- ? in Progression of Fibrotic Renal Disease: Beyond Hemodynamics"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "14"
        "paginaFinal" => "15"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "W. A. BORDER"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "W. A. BORDER"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «TGF-BETA EN LA PROGRESIÓN DE LA LESIÓN RENAL» Angiotensin II and TGF- in Progression of Fibrotic Renal Disease: Beyond Hemodynamics W. A. Border Fibrosis Research Laboratory. Salt Lake City. Utah. Better understanding of the hemodynamic-independent actions of the renin-angiotensin system (RAS) may lead to improved therapies for renal fibrosis. The conventional view of the RAS is that its role is solely hemodynamic. The RAS maintains systemic blood pressure, modulates glomerular pressure and flow and regulates sodium and potassium transport in the renal tubule. Pharmacologic blockade of the RAS is beneficial in treating hypertension, as well as primary renal and cardiac diseases. The therapeutic benefits are attributed to blocking the hemodynamic effects of RAS e.g., lowering blood pressure or intraglomerular pressure. Of course this is all true, but it appears to be only part of the explanation of the therapeutic effects. Recent findings from several laboratories using different experimental approaches have revealed a whole new dimension to the RAS that is beyond the realm of hemodynamics. This new understanding of the RAS has important clinical implications. It predicts and explains why blockade of the RAS, with angiotensin converting enzyme (ACE) inhibitors, the newer receptor antagonists or both together will significantly slow the progression of renal disease but not stop it i.e., renal protection, but not prevention. However, it further suggests that a combination of angiotensin II blockade with another agent(s) may truly halt progressive fibrosis. The new picture of the biological role of the RAS that is emerging is that it is best viewed as part of a system of interconnected emergency «911» molecules designed to be activated following tissue injury. Correspondence: Wayne A. Border M. D. Fibrosis Research Laboratory 391 Chipeta Way, Suite E Salt Lake City, Utah 84108 The purpose of the «911» molecules is to preserve biological integrity and function by maintaining blood flow, stopping hemorrhage, and initiating the complex task of tissue repair. A paradigm for «911» molecules is the recent discovery that angiotensin II stimulates and enhances the production of both plasminogen activator inhibitor-type I (PAI-I) and transforming growth factor- (TGF-). Why this interconnection? The vital role of the RAS in maintaining blood pressure and organ perfusion in response to volume depletion or blood loss is well understood. PAI-I is key to stabilizing a fibrin clot, that stops hemorrhage and which also acts as a provisional matrix at the initiation of tissue repair. PAI-I also facilitates the deposition of new extracellular matrix by preventing its degradation by newly generated plasmin. TGF-'s role is to deposit new extracellular matrix by simultaneously stimulating its synthesis, inhibiting its degradation by also stimulating PAI-I production and by modulating the expression of new cell matrix receptors that facilitate extracellular matrix deposition. TGF- also regulates the actions of other cytokines that induce cell proliferation and angiogenesis. Thus activation of the RAS leads, not only to protective hemodynamic changes, but also to a comprehensive «911» response to repair injured tissue via induction of PAI-I and TGF-. But herein lies two problems with important clinical implications: 1) If the overexpression of PAI-I and TGF- is not terminated, it will lead to pathological accumulation of extracellular matrix which is fibrosis. 2) Although angiotensin II can activate and sustain a «911» response, blockade of angiotensin II with drugs, even at super doses only partially turns the response off. Thus these drugs slow the progression of fibrosis, but do not stop it. There are several possible reasons for this that are not mutually exclusive. For example, the «911» response may be biologically too important to be easily turned off by blocking only one arm or the 14 ANGIOTENSIN II AND TGF- IN PROGRESSION OF FIBROTIC RENAL DISEASE underlying active disease process may continue to activate the system through pathways other than RAS. This suggests that a combination of angioten- sin II blockade with an agent targeted at other factor(s) might normalize TGF- expression and thus halt progressive renal fibrosis. 15 "
    "pdfFichero" => "P7-E170-S140-A1868.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/P7-E170-S140-A1868.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025862?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Angiotensin II and TGF- ? in Progression of Fibrotic Renal Disease: Beyond Hemodynamics
W. A. BORDER
Leído
4048
Veces
se ha leído el artículo
1612
Total PDF
2436
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699500025862"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:14-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1599
    "formatos" => array:3 [
      "EPUB" => 174
      "HTML" => 1156
      "PDF" => 269
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025854"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:16-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2256
      "formatos" => array:3 [
        "EPUB" => 162
        "HTML" => 1700
        "PDF" => 394
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Papel del TGF- ?1 en la progresión de la Nefropatía Crónica del Injerto renal. Efecto del Bloqueo de la Angiotensina II"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "16"
          "paginaFinal" => "17"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. M. CAMPISTOL"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. M. CAMPISTOL"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025854?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025854/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025870"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:13"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2160
      "formatos" => array:3 [
        "EPUB" => 148
        "HTML" => 1629
        "PDF" => 383
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Efectos del Losartan en los cambios de las uniones intercelulares endoteliales mediados por Angiotensina II"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "13"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. ÁLVAREZ CHIVA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. ÁLVAREZ CHIVA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025870?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025870/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Angiotensin II and TGF- ? in Progression of Fibrotic Renal Disease: Beyond Hemodynamics"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "14"
        "paginaFinal" => "15"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "W. A. BORDER"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "W. A. BORDER"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «TGF-BETA EN LA PROGRESIÓN DE LA LESIÓN RENAL» Angiotensin II and TGF- in Progression of Fibrotic Renal Disease: Beyond Hemodynamics W. A. Border Fibrosis Research Laboratory. Salt Lake City. Utah. Better understanding of the hemodynamic-independent actions of the renin-angiotensin system (RAS) may lead to improved therapies for renal fibrosis. The conventional view of the RAS is that its role is solely hemodynamic. The RAS maintains systemic blood pressure, modulates glomerular pressure and flow and regulates sodium and potassium transport in the renal tubule. Pharmacologic blockade of the RAS is beneficial in treating hypertension, as well as primary renal and cardiac diseases. The therapeutic benefits are attributed to blocking the hemodynamic effects of RAS e.g., lowering blood pressure or intraglomerular pressure. Of course this is all true, but it appears to be only part of the explanation of the therapeutic effects. Recent findings from several laboratories using different experimental approaches have revealed a whole new dimension to the RAS that is beyond the realm of hemodynamics. This new understanding of the RAS has important clinical implications. It predicts and explains why blockade of the RAS, with angiotensin converting enzyme (ACE) inhibitors, the newer receptor antagonists or both together will significantly slow the progression of renal disease but not stop it i.e., renal protection, but not prevention. However, it further suggests that a combination of angiotensin II blockade with another agent(s) may truly halt progressive fibrosis. The new picture of the biological role of the RAS that is emerging is that it is best viewed as part of a system of interconnected emergency «911» molecules designed to be activated following tissue injury. Correspondence: Wayne A. Border M. D. Fibrosis Research Laboratory 391 Chipeta Way, Suite E Salt Lake City, Utah 84108 The purpose of the «911» molecules is to preserve biological integrity and function by maintaining blood flow, stopping hemorrhage, and initiating the complex task of tissue repair. A paradigm for «911» molecules is the recent discovery that angiotensin II stimulates and enhances the production of both plasminogen activator inhibitor-type I (PAI-I) and transforming growth factor- (TGF-). Why this interconnection? The vital role of the RAS in maintaining blood pressure and organ perfusion in response to volume depletion or blood loss is well understood. PAI-I is key to stabilizing a fibrin clot, that stops hemorrhage and which also acts as a provisional matrix at the initiation of tissue repair. PAI-I also facilitates the deposition of new extracellular matrix by preventing its degradation by newly generated plasmin. TGF-'s role is to deposit new extracellular matrix by simultaneously stimulating its synthesis, inhibiting its degradation by also stimulating PAI-I production and by modulating the expression of new cell matrix receptors that facilitate extracellular matrix deposition. TGF- also regulates the actions of other cytokines that induce cell proliferation and angiogenesis. Thus activation of the RAS leads, not only to protective hemodynamic changes, but also to a comprehensive «911» response to repair injured tissue via induction of PAI-I and TGF-. But herein lies two problems with important clinical implications: 1) If the overexpression of PAI-I and TGF- is not terminated, it will lead to pathological accumulation of extracellular matrix which is fibrosis. 2) Although angiotensin II can activate and sustain a «911» response, blockade of angiotensin II with drugs, even at super doses only partially turns the response off. Thus these drugs slow the progression of fibrosis, but do not stop it. There are several possible reasons for this that are not mutually exclusive. For example, the «911» response may be biologically too important to be easily turned off by blocking only one arm or the 14 ANGIOTENSIN II AND TGF- IN PROGRESSION OF FIBROTIC RENAL DISEASE underlying active disease process may continue to activate the system through pathways other than RAS. This suggests that a combination of angioten- sin II blockade with an agent targeted at other factor(s) might normalize TGF- expression and thus halt progressive renal fibrosis. 15 "
    "pdfFichero" => "P7-E170-S140-A1868.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025862/v0_201502091333/en/P7-E170-S140-A1868.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025862?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 5 11 16
2024 Octubre 37 40 77
2024 Septiembre 31 24 55
2024 Agosto 41 44 85
2024 Julio 32 35 67
2024 Junio 36 21 57
2024 Mayo 38 31 69
2024 Abril 30 19 49
2024 Marzo 29 26 55
2024 Febrero 31 32 63
2024 Enero 19 18 37
2023 Diciembre 15 19 34
2023 Noviembre 24 32 56
2023 Octubre 28 30 58
2023 Septiembre 19 22 41
2023 Agosto 18 24 42
2023 Julio 21 26 47
2023 Junio 27 16 43
2023 Mayo 28 22 50
2023 Abril 20 15 35
2023 Marzo 14 19 33
2023 Febrero 16 17 33
2023 Enero 27 20 47
2022 Diciembre 27 17 44
2022 Noviembre 23 29 52
2022 Octubre 31 44 75
2022 Septiembre 33 24 57
2022 Agosto 29 30 59
2022 Julio 34 41 75
2022 Junio 21 27 48
2022 Mayo 18 26 44
2022 Abril 29 38 67
2022 Marzo 28 40 68
2022 Febrero 30 36 66
2022 Enero 23 20 43
2021 Diciembre 24 40 64
2021 Noviembre 22 24 46
2021 Octubre 21 46 67
2021 Septiembre 21 22 43
2021 Agosto 23 33 56
2021 Julio 15 27 42
2021 Junio 14 22 36
2021 Mayo 19 27 46
2021 Abril 17 47 64
2021 Marzo 25 16 41
2021 Febrero 22 8 30
2021 Enero 10 14 24
2020 Diciembre 14 7 21
2020 Noviembre 11 11 22
2020 Octubre 15 4 19
2020 Septiembre 11 4 15
2020 Agosto 14 8 22
2020 Julio 11 7 18
2020 Junio 10 8 18
2020 Mayo 13 6 19
2020 Abril 17 10 27
2020 Marzo 8 9 17
2020 Febrero 24 14 38
2020 Enero 30 13 43
2019 Diciembre 10 13 23
2019 Noviembre 3 4 7
2019 Octubre 4 5 9
2019 Septiembre 12 15 27
2019 Agosto 8 8 16
2019 Julio 10 10 20
2019 Junio 5 5 10
2019 Mayo 7 20 27
2019 Abril 35 22 57
2019 Marzo 9 6 15
2019 Febrero 7 11 18
2019 Enero 9 5 14
2018 Diciembre 17 17 34
2018 Noviembre 19 7 26
2018 Octubre 16 8 24
2018 Septiembre 20 6 26
2018 Agosto 20 7 27
2018 Julio 14 5 19
2018 Junio 10 4 14
2018 Mayo 15 13 28
2018 Abril 16 2 18
2018 Marzo 10 2 12
2018 Febrero 14 5 19
2018 Enero 8 4 12
2017 Diciembre 11 5 16
2017 Noviembre 13 5 18
2017 Octubre 15 2 17
2017 Septiembre 12 3 15
2017 Agosto 18 7 25
2017 Julio 13 2 15
2017 Junio 15 5 20
2017 Mayo 9 0 9
2017 Abril 11 1 12
2017 Marzo 14 1 15
2017 Febrero 8 2 10
2017 Enero 4 0 4
2016 Diciembre 17 2 19
2016 Noviembre 22 3 25
2016 Octubre 40 5 45
2016 Septiembre 29 2 31
2016 Agosto 50 1 51
2016 Julio 51 0 51
2016 Junio 65 0 65
2016 Mayo 74 0 74
2016 Abril 26 0 26
2016 Marzo 30 0 30
2016 Febrero 31 0 31
2016 Enero 31 0 31
2015 Diciembre 49 0 49
2015 Noviembre 37 0 37
2015 Octubre 28 0 28
2015 Septiembre 29 0 29
2015 Agosto 21 0 21
2015 Julio 20 0 20
2015 Junio 8 0 8
2015 Mayo 14 0 14
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?